Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

OWN it! Necessidades de Formação e Desenvolvimento FY24

Tenha um papel ativo no seu desenvolvimento pessoal. Siga o novo processo para identificar e planear as suas necessidades de formação e desenvolvimento para o ano fiscal 2024.

Page
Read more

Hovione DMFs at FDA

List of DMFs

Page
Read more

Covid-19 / Coronavirus

Stay updated with the latest information on Covid-19

Page
Read more